Sab Biotherapeutics Inc. (SABS)
NASDAQ (CM) NASDAQ (CM) Primary Summary
SABS Chart
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
SAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sab Biotherapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 50 | $227 | $181.25 | -$45.75 | -20.15% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 15,100 | $57,833 | $54,737.5 | -$3,095.5 | -5.35% |
| WTM W. Travis McKinney HB Wealth Management LLC | 307,500 | $618,075 | $1.08M | $464,325 | 75.12% |
 Kevin Roan Stempoint Capita LLP | 375,000 | $1.42M | $1.35M | -$71,184.85 | -5% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 161 | $617 | $575.57 | -$41.43 | -6.71% |
Sab Biotherapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Eliana Merle Barclays | 483.23 | $1,855.61 | $1,763.79 | -$91.82 | -4.95% |
| RS Roger Song Jefferies | 4,397.54 | $15,962.16 | $15,919.09 | -$43.07 | -0.27% |
| EW Edward White HC Wainwright & Co. | -141,296.67 | $353,241.68 | $511,493.95 | -$158,252.27 | -44.8% |
| EB Emily Bodnar HC Wainwright & Co. | 2,125.85 | $8,226.21 | $7,695.58 | -$530.63 | -6.45% |
Sab Biotherapeutics Inc. (SABS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sab Biotherapeutics Inc. ever had a stock split?
Sab Biotherapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Samuel J. Reich CEO | NASDAQ (CM) Exchange | 78397T202 CUSIP |
| US Country | 86 Employees | - Last Dividend | 5 Jan 2024 Last Split | 9 Feb 2021 IPO Date |
Overview
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement of immunotherapies based on human antibodies for a wide range of diseases. Utilizing cutting-edge genetic engineering and antibody science, the company has developed transchromosomic cattle herds that produce fully human antibodies. These antibodies are aimed at combating infectious diseases, immune and autoimmune disorders, including a plethora of conditions from influenza to oncology. Founded in 2014 and headquartered in Sioux Falls, South Dakota, SAB Biotherapeutics leverages its proprietary DiversitAb platform to generate fully-human polyclonal antibodies without relying on human donors or plasma, setting a new standard in the field of biopharmaceuticals.
Products and Services
SAB-185: A leading product candidate from SAB Biotherapeutics, SAB-185 is a fully-human polyclonal antibody therapeutic currently in Phase III clinical trials aimed at the treatment of COVID-19. This candidate represents a groundbreaking approach in the fight against the pandemic, showcasing the company's expertise in harnessing the power of human antibodies for therapeutic use.
SAB-176: Another promising therapeutic candidate, SAB-176, is in the pipeline for the treatment or prevention of severe influenza. As a fully-human polyclonal antibody, SAB-176 leverages the company’s technology to possibly offer a new solution to a longstanding global health threat. Its development is closely watched for its potential to address a critical unmet medical need.
DiversitAb Immunotherapy Platform: The cornerstone of SAB Biotherapeutics’ product offering, the DiversitAb platform, enables the production of fully-human polyclonal antibodies without the need for human plasma donors. This innovative platform not only broadens the scope of treatable conditions but also enhances the safety profile of the antibodies produced, making it a significant advancement in immunotherapy.
Pre-Clinical Product Candidates: SAB Biotherapeutics is also developing pre-clinical product candidates for autoimmune diseases, including SAB-142 for type 1 diabetes and for use in organ transplantation induction/rejection. These early-stage projects reflect the company’s commitment to leveraging its technology to address a wide array of immune and autoimmune disorders, with the potential to significantly impact patients' lives worldwide.
